{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T23:38:00Z","timestamp":1787701080348,"version":"build-2784847793"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"DOI":"10.1186\/s13104-026-07781-y","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T04:46:32Z","timestamp":1773981992000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Subtherapeutic exposure in doxorubicin pharmacokinetics among Ugandan breast cancer patients: a pilot study with implications for personalized therapy"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1762-5918","authenticated-orcid":false,"given":"Dave","family":"Darshit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osinde","family":"Godfrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Sekaggya-Wiltshire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mukonzo","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald Kadada","family":"Karyaburo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Buzibye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Omali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nixon","family":"Niyonzima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjanaa","family":"Srikant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhara","family":"Dave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,20]]},"reference":[{"key":"7781_CR1","unstructured":"WHO. Breast cancer. 2022. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/breast-cancer."},{"key":"7781_CR2","unstructured":"Nyineizooba VA, Isabirye J. The impact of breast cancer awareness campaigns on women\u2019s knowledge, attitudes, and practices in Uganda\u2019s Kampala district. 2024."},{"issue":"5","key":"7781_CR3","first-page":"1568","volume":"10","author":"FZ Francies","year":"2020","unstructured":"Francies FZ, Hull R, Khanyile R, Dlamini Z. Breast cancer in low-middle income countries: abnormality in splicing and lack of targeted treatment options. Am J Cancer Res. 2020;10(5):1568\u201391.","journal-title":"Am J Cancer Res"},{"issue":"7","key":"7781_CR4","doi-asserted-by":"publisher","first-page":"e0219601","DOI":"10.1371\/journal.pone.0219601","volume":"14","author":"T Ekdahl Hjelm","year":"2019","unstructured":"Ekdahl Hjelm T, Matovu A, Mugisha N, L\u00f6fgren J. Breast cancer care in Uganda: A multicenter study on the frequency of breast cancer surgery in relation to the incidence of breast cancer. PLoS ONE. 2019;14(7):e0219601.","journal-title":"PLoS ONE"},{"issue":"2","key":"7781_CR5","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/sj.bjc.6604174","volume":"98","author":"R Bowen","year":"2008","unstructured":"Bowen R, Duffy S, Ryan D, Hart I, Jones J. Early onset of breast cancer in a group of British black women. Br J Cancer. 2008;98(2):277\u201381.","journal-title":"Br J Cancer"},{"key":"7781_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13104-015-1438-8","volume":"8","author":"J Odongo","year":"2015","unstructured":"Odongo J, Makumbi T, Kalungi S, Galukande M. Patient delay factors in women presenting with breast cancer in a low income country. BMC Res Notes. 2015;8:1\u20136.","journal-title":"BMC Res Notes"},{"key":"7781_CR7","doi-asserted-by":"publisher","first-page":"249","DOI":"10.11604\/pamj.2014.17.249.3305","volume":"17","author":"M Galukande","year":"2014","unstructured":"Galukande M, Wabinga H, Mirembe F, Karamagi C, Asea A. Molecular breast cancer subtypes prevalence in an indigenous Sub Saharan African population. Pan Afr Med J. 2014;17:249.","journal-title":"Pan Afr Med J"},{"issue":"1","key":"7781_CR8","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1097\/PPO.0b013e3181d24ff7","volume":"16","author":"SJ Isakoff","year":"2010","unstructured":"Isakoff SJ. Triple-negative breast cancer: role of specific chemotherapy agents. Cancer J. 2010;16(1):53\u201361.","journal-title":"Cancer J"},{"key":"7781_CR9","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.bbacli.2015.03.003","volume":"3","author":"EA O\u2019Reilly","year":"2015","unstructured":"O\u2019Reilly EA, Gubbins L, Sharma S, Tully R, Guang MHZ, Weiner-Gorzel K, et al. The fate of chemoresistance in triple negative breast cancer (TNBC). BBA Clin. 2015;3:257\u201375.","journal-title":"BBA Clin"},{"issue":"4","key":"7781_CR10","doi-asserted-by":"publisher","first-page":"659","DOI":"10.3390\/cells12040659","volume":"12","author":"M Kciuk","year":"2023","unstructured":"Kciuk M, Gieleci\u0144ska A, Mujwar S, Ko\u0142at D, Ka\u0142uzi\u0144ska-Ko\u0142at \u017b, Celik I, et al. Doxorubicin-an agent with multiple mechanisms of anticancer activity. Cells. 2023;12(4):659.","journal-title":"Cells"},{"issue":"2","key":"7781_CR11","first-page":"126","volume":"8","author":"A Gakwaya","year":"2008","unstructured":"Gakwaya A, Galukande M, Luwaga A, Jombwe J, Fualal J, Kiguli-Malwadde E, et al. Breast cancer guidelines Uganda (2008) Afr Health Sci. 2008;8(2):126.","journal-title":"Breast cancer guidelines Uganda (2008) Afr Health Sci"},{"key":"7781_CR12","unstructured":"Lu F. Pharmacodynamics, pharmacokinetics and pharmacogenetics of doxorubicin in Singaporean breast cancer patients (doctoral dissertation). 2009."},{"issue":"1","key":"7781_CR13","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/sj.bjc.6604435","volume":"99","author":"A Gakwaya","year":"2008","unstructured":"Gakwaya A, Kigula-Mugambe J, Kavuma A, Luwaga A, Fualal J, Jombwe J, et al. Cancer of the breast: 5-year survival in a tertiary hospital in Uganda. Br J Cancer. 2008;99(1):63\u20137.","journal-title":"Br J Cancer"},{"issue":"9","key":"7781_CR14","doi-asserted-by":"publisher","first-page":"108528","DOI":"10.1016\/j.ejso.2024.108528","volume":"50","author":"M Gedfew","year":"2024","unstructured":"Gedfew M, Getie A, Akalu TY, Ayenew T. Recurrence and associated factors of breast cancer among women in Sub Saharan Africa, systematic review and meta-analysis. Eur J Surg Oncol. 2024;50(9):108528.","journal-title":"Eur J Surg Oncol"},{"key":"7781_CR15","doi-asserted-by":"publisher","first-page":"S1512","DOI":"10.21037\/tcr.2017.09.14","volume":"6","author":"AS Darwich","year":"2017","unstructured":"Darwich AS, Ogungbenro K, Hatley OJ, Rostami-Hodjegan A. Role of pharmacokinetic modeling and simulation in precision dosing of anticancer drugs. Transl Cancer Res. 2017;6:S1512\u201329.","journal-title":"Transl Cancer Res"},{"issue":"24","key":"7781_CR16","doi-asserted-by":"publisher","first-page":"8027","DOI":"10.1158\/1078-0432.CCR-08-0993","volume":"14","author":"S-H Tan","year":"2008","unstructured":"Tan S-H, Lee S-C, Goh B-C, Wong J. Pharmacogenetics in breast cancer therapy. Clin Cancer Res. 2008;14(24):8027\u201341.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"7781_CR17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/ajco.13776","volume":"19","author":"J Methaneethorn","year":"2023","unstructured":"Methaneethorn J, Tengcharoen K, Leelakanok N, AlEjielat R. Population pharmacokinetics of doxorubicin: A systematic review. Asia-Pac J Clin Oncol. 2023;19(1):9\u201326.","journal-title":"Asia-Pac J Clin Oncol"},{"issue":"1","key":"7781_CR18","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s10549-014-2843-8","volume":"144","author":"AL Wong","year":"2014","unstructured":"Wong AL, Seng KY, Ong EM, Wang LZ, Oscar H, Cordero MT, et al. Body fat composition impacts the hematologic toxicities and pharmacokinetics of doxorubicin in Asian breast cancer patients. Breast Cancer Res Treat. 2014;144(1):143\u201352.","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"7781_CR19","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.ejca.2003.12.026","volume":"40","author":"MA Rudek","year":"2004","unstructured":"Rudek MA, Sparreboom A, Garrett-Mayer ES, Armstrong DK, Wolff AC, Verweij J, et al. Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy. Eur J Cancer. 2004;40(8):1170\u20138.","journal-title":"Eur J Cancer"},{"issue":"5","key":"7781_CR20","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/clpt.1993.69","volume":"53","author":"SC Piscitelli","year":"1993","unstructured":"Piscitelli SC, Rodvold KA, Rushing DA, Tewksbury DA. Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer. Clin Pharmacol Ther. 1993;53(5):555\u201361.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"7781_CR21","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1002\/cam4.2728","volume":"9","author":"VM Villalobos","year":"2020","unstructured":"Villalobos VM, Mo G, Agulnik M, Pollack SM, Rushing DA, Singh A, et al. Pharmacokinetics of doxorubicin following concomitant intravenous administration of olaratumab (IMC-3G3) to patients with advanced soft tissue sarcoma. Cancer Med. 2020;9(3):882\u201393.","journal-title":"Cancer Med"},{"issue":"3","key":"7781_CR22","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1556\/1326.2023.01129","volume":"36","author":"K Zhang","year":"2024","unstructured":"Zhang K, Zhang D, Ge Z, Qiu F. Development and validation of an LC-MS\/MS method for the quantification of free and total doxorubicin in human plasma and its clinical application for a novel doxorubicin hydrochloride liposome injection in Chinese patients with breast cancer. Acta Chromatographica. 2024;36(3):186\u201395.","journal-title":"Acta Chromatographica"},{"key":"7781_CR23","doi-asserted-by":"publisher","first-page":"100263","DOI":"10.1016\/j.jcpo.2020.100263","volume":"27","author":"A Nakaganda","year":"2021","unstructured":"Nakaganda A, Solt K, Kwagonza L, Driscoll D, Kampi R, Orem J. Challenges faced by cancer patients in Uganda: Implications for health systems strengthening in resource limited settings. J Cancer Policy. 2021;27:100263.","journal-title":"J Cancer Policy"},{"issue":"1","key":"7781_CR24","doi-asserted-by":"publisher","first-page":"327","DOI":"10.4314\/ahs.v22i1.40","volume":"22","author":"S Kibudde","year":"2022","unstructured":"Kibudde S, Namisango E, Nakaganda A, Atieno M, Bbaale J, Nabwana M, et al. Turnaround time and barriers to treatment of newly diagnosed cancer in Uganda: a mixed-methods longitudinal study. Afr Health Sci. 2022;22(1):327\u201337.","journal-title":"Afr Health Sci"},{"issue":"1","key":"7781_CR25","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13027-017-0124-y","volume":"12","author":"V Vanderpuye","year":"2017","unstructured":"Vanderpuye V, Grover S, Hammad N, PoojaPrabhakar, Simonds H, Olopade F, et al. An update on the management of breast cancer in Africa. Infect Agents Cancer. 2017;12(1):13.","journal-title":"Infect Agents Cancer"},{"key":"7781_CR26","unstructured":"Administration FD, M10 bioanalytical method validation and study sample analysis. 2022. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/m10-bioanalytical-method-validation-and-study-sample-analysis."},{"key":"7781_CR27","unstructured":"Agency EM. ICH M10 on bioanalytical method validation-scientific guideline. 2023. https:\/\/www.ema.europa.eu\/en\/ich-m10-bioanalytical-method-validation-scientific-guideline."},{"key":"7781_CR28","unstructured":"Core RT. R: a language and environment for statistical computing. 2019."},{"key":"7781_CR29","unstructured":"Andrew Stein AM, Khanshan F, Konstantin Krismer. xgxr: exploratory graphics for pharmacometrics. 2023. https:\/\/opensource.nibr.com\/xgx\/."},{"issue":"3","key":"7781_CR30","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1007\/s12609-018-0278-7","volume":"10","author":"JR Scheel","year":"2018","unstructured":"Scheel JR, Anderson S, Foerster M, Galukande M, McCormack V. Factors contributing to late-stage breast cancer presentation in sub-Saharan Africa. Curr Breast Cancer Rep. 2018;10(3):142\u20137.","journal-title":"Curr Breast Cancer Rep"},{"issue":"3\u20134","key":"7781_CR31","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.ejps.2010.07.015","volume":"41","author":"DR Barpe","year":"2010","unstructured":"Barpe DR, Rosa DD, Froehlich PE. Pharmacokinetic evaluation of doxorubicin plasma levels in normal and overweight patients with breast cancer and simulation of dose adjustment by different indexes of body mass. Eur J Pharm Sci. 2010;41(3\u20134):458\u201363.","journal-title":"Eur J Pharm Sci"},{"issue":"9","key":"7781_CR32","first-page":"4467","volume":"43","author":"J Robert","year":"1983","unstructured":"Robert J, Hoerni B. Age dependence of the early-phase pharmacokinetics of doxorubicin. Cancer Res. 1983;43(9):4467\u20139.","journal-title":"Cancer Res"},{"issue":"1","key":"7781_CR33","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2165\/00003088-198815010-00002","volume":"15","author":"PA Speth","year":"1988","unstructured":"Speth PA, van Hoesel QG, Haanen C. Clinical pharmacokinetics of doxorubicin. Clin Pharmacokinet. 1988;15(1):15\u201331.","journal-title":"Clin Pharmacokinet"},{"key":"7781_CR34","volume-title":"Prevalence of genetic polymorphisms associated with anti-cancer drug efficacy and toxicity in the South African population","author":"B Sansom","year":"2021","unstructured":"Sansom B. Prevalence of genetic polymorphisms associated with anti-cancer drug efficacy and toxicity in the South African population. University of Pretoria (South Africa): Hatfield; 2021."},{"issue":"10","key":"7781_CR35","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1111\/j.1349-7006.2008.00903.x","volume":"99","author":"S Lal","year":"2008","unstructured":"Lal S, Sandanaraj E, Wong ZW, Ang PC, Wong NS, Lee EJ, et al. CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients. Cancer Sci. 2008;99(10):2045\u201354.","journal-title":"Cancer Sci"},{"issue":"7","key":"7781_CR36","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1097\/FPC.0b013e328301a869","volume":"18","author":"L Fan","year":"2008","unstructured":"Fan L, Goh B-C, Wong C-I, Sukri N, Lim S-E, Tan S-H, et al. Genotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicity. Pharmacogenet Genomics. 2008;18(7):623\u201331.","journal-title":"Pharmacogenet Genomics"},{"key":"7781_CR37","first-page":"613","volume":"15","author":"KC Nthontho","year":"2022","unstructured":"Nthontho KC, Ndlovu AK, Sharma K, Kasvosve I, Hertz DL, Paganotti GM. Pharmacogenetics of Breast Cancer Treatments: A Sub-Saharan Africa Perspective. Pharmgenomics Pers Med. 2022;15:613\u201352.","journal-title":"Pharmgenomics Pers Med"},{"issue":"21","key":"7781_CR38","doi-asserted-by":"publisher","first-page":"5436","DOI":"10.3390\/cancers14215436","volume":"14","author":"AA Bagdasaryan","year":"2022","unstructured":"Bagdasaryan AA, Chubarev VN, Smolyarchuk EA, Drozdov VN, Krasnyuk II, Liu J, et al. Pharmacogenetics of drug metabolism: the role of gene polymorphism in the regulation of doxorubicin safety and efficacy. Cancers. 2022;14(21):5436.","journal-title":"Cancers"},{"issue":"4","key":"7781_CR39","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1111\/j.1349-7006.2008.00744.x","volume":"99","author":"S Lal","year":"2008","unstructured":"Lal S, Wong ZW, Sandanaraj E, Xiang X, Ang PCS, Lee EJ, et al. Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients. Cancer Sci. 2008;99(4):816\u201323.","journal-title":"Cancer Sci"},{"issue":"1","key":"7781_CR40","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/cas.12560","volume":"106","author":"HJ Kim","year":"2015","unstructured":"Kim HJ, Im SA, Keam B, Ham HS, Lee KH, Kim TY, et al. ABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy. Cancer Sci. 2015;106(1):86\u201393.","journal-title":"Cancer Sci"},{"issue":"1","key":"7781_CR41","first-page":"19","volume":"2","author":"AH Salem","year":"2014","unstructured":"Salem AH, Ali M, Ibrahim A, Ibrahim M. Genotype and allele frequencies of MDR-1 gene polymorphism in Jordanian and Sudanese populations. Am J Med Stud. 2014;2(1):19\u201323.","journal-title":"Am J Med Stud"},{"issue":"1","key":"7781_CR42","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s13539-011-0022-x","volume":"2","author":"L Santarpia","year":"2011","unstructured":"Santarpia L, Contaldo F, Pasanisi F. Nutritional screening and early treatment of malnutrition in cancer patients. J Cachexia Sarcopenia Muscle. 2011;2(1):27\u201335.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"12","key":"7781_CR43","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S1470-2045(08)70307-3","volume":"9","author":"KM Field","year":"2008","unstructured":"Field KM, Michael M, Part II. Liver function in oncology: towards safer chemotherapy use. Lancet Oncol. 2008;9(12):1181\u201390.","journal-title":"Lancet Oncol"},{"issue":"2","key":"7781_CR44","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.4102\/ajlm.v9i2.1103","volume":"9","author":"P Ondoa","year":"2020","unstructured":"Ondoa P, Ndlovu N, Keita MS, Massinga-Loembe M, Kebede Y, Odhiambo C, et al. Preparing national tiered laboratory systems and networks to advance diagnostics in Africa and meet the continent\u2019s health agenda: Insights into priority areas for improvement. Afr J Lab Med. 2020;9(2):1103.","journal-title":"Afr J Lab Med"},{"key":"7781_CR45","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.3389\/fonc.2019.01356","volume":"9","author":"PS Fasinu","year":"2019","unstructured":"Fasinu PS, Rapp GK. Herbal Interaction With Chemotherapeutic Drugs-A Focus on Clinically Significant Findings. Front Oncol. 2019;9:1356.","journal-title":"Front Oncol"},{"issue":"3","key":"7781_CR46","doi-asserted-by":"publisher","first-page":"195","DOI":"10.4155\/ipk-2017-0004","volume":"2","author":"AD McCallum","year":"2017","unstructured":"McCallum AD, Sloan DJ. The importance of clinical pharmacokinetic-pharmacodynamic studies in unraveling the determinants of early and late tuberculosis outcomes. Int J Pharmacokinet. 2017;2(3):195\u2013212.","journal-title":"Int J Pharmacokinet"},{"issue":"12","key":"7781_CR47","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.2165\/00003088-200746120-00005","volume":"46","author":"M Joerger","year":"2007","unstructured":"Joerger M, Huitema AD, Richel DJ, Dittrich C, Pavlidis N, Briasoulis E, et al. Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG. Clin Pharmacokinet. 2007;46(12):1051\u201368.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"7781_CR48","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1177\/107327481602300404","volume":"23","author":"LM Hamel","year":"2016","unstructured":"Hamel LM, Penner LA, Albrecht TL, Heath E, Gwede CK, Eggly S. Barriers to Clinical Trial Enrollment in Racial and Ethnic Minority Patients With Cancer. Cancer Control. 2016;23(4):327\u201337.","journal-title":"Cancer Control"},{"key":"7781_CR49","unstructured":"Forum WE. Improving access to innovative medicines in Africa starts with clinical trials. 2025. https:\/\/www.weforum.org\/stories\/2025\/07\/healthcare-access-africa-clinical-trials\/."},{"issue":"1","key":"7781_CR50","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12939-025-02431-4","volume":"24","author":"S Pardhan","year":"2025","unstructured":"Pardhan S, Sehmbi T, Wijewickrama R, Onumajuru H, Piyasena MP. Barriers and facilitators for engaging underrepresented ethnic minority populations in healthcare research: an umbrella review. Int J Equity Health. 2025;24(1):70.","journal-title":"Int J Equity Health"},{"issue":"1","key":"7781_CR51","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41392-024-01808-1","volume":"9","author":"Y Xia","year":"2024","unstructured":"Xia Y, Sun M, Huang H, Jin W-L. Drug repurposing for cancer therapy. Signal Transduct Target Therapy. 2024;9(1):92.","journal-title":"Signal Transduct Target Therapy"},{"key":"7781_CR52","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s12957-015-0632-4","volume":"13","author":"M Galukande","year":"2015","unstructured":"Galukande M, Wabinga H, Mirembe F. Breast cancer survival experiences at a tertiary hospital in sub-Saharan Africa: a cohort study. World J Surg Oncol. 2015;13:220.","journal-title":"World J Surg Oncol"},{"issue":"2","key":"7781_CR53","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S1470-2045(09)70335-3","volume":"11","author":"R Sankaranarayanan","year":"2010","unstructured":"Sankaranarayanan R, Swaminathan R, Brenner H, Chen K, Chia KS, Chen JG, et al. Cancer survival in Africa, Asia, and Central America: a population-based study. Lancet Oncol. 2010;11(2):165\u201373.","journal-title":"Lancet Oncol"},{"key":"7781_CR54","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.jconrel.2022.10.043","volume":"352","author":"L DeRidder","year":"2022","unstructured":"DeRidder L, Rubinson DA, Langer R, Traverso G. The past, present, and future of chemotherapy with a focus on individualization of drug dosing. J Controlled Release. 2022;352:840\u201360.","journal-title":"J Controlled Release"},{"issue":"8","key":"7781_CR55","doi-asserted-by":"publisher","first-page":"205427041453112","DOI":"10.1177\/2054270414531121","volume":"5","author":"N Nwobodo","year":"2014","unstructured":"Nwobodo N. Therapeutic drug monitoring in a developing nation: a clinical guide. JRSM Open. 2014;5(8):2054270414531121.","journal-title":"JRSM Open"},{"key":"7781_CR56","doi-asserted-by":"publisher","first-page":"e2300439","DOI":"10.1200\/GO.23.00439","volume":"10","author":"OA Bamodu","year":"2024","unstructured":"Bamodu OA, Chung CC. Cancer care disparities: overcoming barriers to cancer control in low- and middle-income countries. JCO Glob Oncol. 2024;10:e2300439.","journal-title":"JCO Glob Oncol"},{"issue":"4","key":"7781_CR57","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/s41591-022-01738-x","volume":"28","author":"CS Pramesh","year":"2022","unstructured":"Pramesh CS, Badwe RA, Bhoo-Pathy N, Booth CM, Chinnaswamy G, Dare AJ, et al. Priorities for cancer research in low- and middle-income countries: a global perspective. Nat Med. 2022;28(4):649\u201357.","journal-title":"Nat Med"},{"key":"7781_CR58","doi-asserted-by":"publisher","first-page":"e2400114","DOI":"10.1200\/GO.24.00114","volume":"10","author":"D Pain","year":"2024","unstructured":"Pain D, MacDuffie E, Martei YM, Kassick M, Ikeda DJ, Shulman LN, et al. Barriers to Implementing a Quality Improvement Program in Low- and Middle-Income Countries: Adequacy of Resources. JCO Glob Oncol. 2024;10:e2400114.","journal-title":"JCO Glob Oncol"},{"issue":"5","key":"7781_CR59","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.gpb.2016.03.008","volume":"14","author":"S Ahmed","year":"2016","unstructured":"Ahmed S, Zhou Z, Zhou J, Chen SQ. Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine. Genomics Proteom Bioinf. 2016;14(5):298\u2013313.","journal-title":"Genomics Proteom Bioinf"}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13104-026-07781-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-026-07781-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-026-07781-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T01:02:40Z","timestamp":1777424560000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13104-026-07781-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,20]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7781"],"URL":"https:\/\/doi.org\/10.1186\/s13104-026-07781-y","relation":{},"ISSN":["1756-0500"],"issn-type":[{"value":"1756-0500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,20]]},"assertion":[{"value":"18 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study complies with the declaration of Helsinki on research involving human subjects. The study was approved by Uganda Cancer Institute-REC (UCI- REF: 20\/2017) and Uganda National Council for Science and Technology (HS239ES). Enrolment was solely voluntary with written informed consent. Participants were however free to withdraw from the study at any time point. Identification numbers instead of names were used and data collected were treated with utmost confidentiality.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"194"}}